Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Off-Label Use of Atypical Antipsychotics: An Update

Slide: 44 of 47

Conclusions (1 of 3)

Atypical antipsychotics can improve behavioral symptoms of dementia, although the effect sizes are considered to be small in magnitude.

Several atypical antipsychotics are approved for treating major depressive disorder, and additional members of the class show evidence of efficacy.

  • Risperidone (Strength of Evidence = Moderate)
  • Ziprasidone (Strength of Evidence = Low)
  • Quetiapine XR monotherapy (Strength of Evidence = Moderate)

There is a growing evidence base for the efficacy of individual atypical antipsychotics in treating these disorders:

  • Obsessive-compulsive disorder: Risperidone (Strength of Evidence = Moderate)
  • Post-traumatic stress disorder (combat-related): Risperidone (Strength of Evidence = Moderate)
  • Generalized anxiety disorder: Quetiapine (Strength of Evidence = Moderate)
  • Borderline personality disorder: Aripiprazole and Olanzapine (Strength of Evidence = Low)